Burning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness

Burning Rock Biotech

10/09/2026 12:29

Overview
China precision oncology NGS firm's Q2 revenue fell 9% yr/yr, driven by lower pharma and lab volumes
Net loss for Q2 widened compared to last year
Company's operating expenses declined 3% yr/yr due to cost controls

Outlook
Burning Rock expects new product registration certificates in coming quarters
Company anticipates sustainable and meaningful top-line growth over the long term

Result Drivers
CENTRAL LAB TEST VOLUME - Revenue from central laboratory business fell 10% due to fewer tests as co continued its transition toward in-hospital business
IN-HOSPITAL SALES GROWTH - In-hospital business revenue rose 7.4%, driven by increased sales volume
PHARMA SERVICES DECLINE - Pharma research and development services revenue dropped 31.8% due to decreased testing for pharma customers

Company press release: ID:nGNX500vw5

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
RMB 134.70 mln
 
Q2 Net Loss
 
RMB 18.40 mln
 
Q2 Adjusted Gross Margin
 
74.30%
 
Q2 Gross Profit
 
RMB 97.80 mln
 
Q2 Operating Expenses
 
RMB 115.80 mln
 

Reuters Recommended Reads
Sept 8 - China's 17EdTech Q2 revenue jumps 254% on expansion of consumer-facing AI application, posts first profit

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)